Sweet syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly female

Dermatol Ther. 2021 Nov;34(6):e15146. doi: 10.1111/dth.15146. Epub 2021 Oct 7.


Vaccination for COVID19 infection is in full swing all around the world and while the vaccines are considered overall safe, many cutaneous and extracutaneous adverse effects have been reported after their use. Local injection-site reactions are the commonest adverse effect described with the use of these vaccines. We describe a case of Sweet syndrome in an elderly female after the first dose of Oxford-AstraZeneca COVID-19 vaccine (AZD1222).

Keywords: COVID vaccine; Sweet syndrome; adverse effects; skin.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • COVID-19 Vaccines
  • COVID-19*
  • ChAdOx1 nCoV-19
  • Female
  • Humans
  • SARS-CoV-2
  • Sweet Syndrome* / chemically induced
  • Sweet Syndrome* / diagnosis


  • COVID-19 Vaccines
  • ChAdOx1 nCoV-19